TAK-994 - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)

CVGI surges 54% as CVG names Zoox strategic supplier and issues $700M revenue outlook for 2026

Representative image illustrating rising takeover speculation around Papa John’s International, Inc., as renewed private equity interest and a reported $65-per-share bid from TriArtisan Capital Advisors push the PZZA stock back into focus amid ongoing turnaround efforts.

Papa John’s agrees to explore sale as renewed private equity interest lifts PZZA

Could Turtle Pond discoveries extend the geological story behind Kenbridge nickel? (CSE: TN)

Takeda terminates TAK-994 program after uncovering hepatotoxicity in Phase 2 Narcolepsy study

Read More

2 minute read

Pharma Industry News

Takeda halts TAK-994 narcolepsy treatment development due to hepatotoxicity concerns

Takeda’s pioneering Phase 2 trial of TAK-994, a potential treatment for narcolepsy type 1 (NT1), came to an…

byPallavi Madhiraju

July 28, 2023

web analytics